Page 6 - மைய மருந்துகள் தரநிலைகள் கட்டுப்பாடு ஆர்கநைஸேஶந் News Today : Breaking News, Live Updates & Top Stories | Vimarsana

Karnataka sets 24-hr deadline for Cipla, Jubilant to supply Remdesivir Roche India on Monday announced the rollout of its first batch of the antibody cocktail (Casirivimab and Imdevimab) against Coronavirus in India. The cocktail drug will be marketed by Cipla pan-India. The second batch of the cocktail jabs will be made available by mid-June. Together, they can potentially benefit 200,000 patients as each of the 100,000 packs that will be available in India offers treatment for two patients, the company said in a statement. The price for each patient dose [a combined dose of 1200 mg (600 mg of Casirivimab and 600 mg of Imdevimab)] will be Rs 59,750. The maximum retail price for the multi-dose pack (each pack can treat two patients) is Rs 119,500, the statement added.

V simpson emmanuelUmang vohraCasirivimab imdevimabCentral drugs standards control organisationRepresentational pictureManaging directorRoche pharma indiaEmergency use authorisationவ் சிம்ப்சன் இம்மானுவேல்உமங் வோஹ்ராமைய மருந்துகள் தரநிலைகள் கட்டுப்பாடு ஆர்கநைஸேஶந்நிர்வகித்தல் இயக்குனர்ரோச் பார்மா இந்தியா